Shares of KALA BIO, Inc. (NASDAQ:KALA – Free Report) are going to reverse split on Monday, November 16th. The 1-30 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, November 15th.
KALA BIO Stock Down 5.8%
Shares of KALA BIO stock traded down $0.01 on Thursday, reaching $0.16. The company’s stock had a trading volume of 381,307 shares, compared to its average volume of 538,570. The firm’s fifty day simple moving average is $0.35 and its two-hundred day simple moving average is $5.81. KALA BIO has a 52 week low of $0.11 and a 52 week high of $95.50. The company has a market capitalization of $3.11 million, a price-to-earnings ratio of -0.01 and a beta of -2.19.
KALA BIO (NASDAQ:KALA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($21.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.00) by ($15.32).
Analyst Upgrades and Downgrades
KALA has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of KALA BIO from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of KALA BIO in a research note on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, KALA BIO presently has a consensus rating of “Sell”.
Read Our Latest Stock Report on KALA
Institutional Investors Weigh In On KALA BIO
A hedge fund recently bought a new stake in KALA BIO stock. BlackRock Inc. bought a new stake in KALA BIO, Inc. (NASDAQ:KALA – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 71,542 shares of the company’s stock, valued at approximately $124,000. BlackRock Inc. owned about 0.37% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is currently owned by institutional investors and hedge funds.
About KALA BIO
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases. The company is centered on its mesenchymal stem cell secretome platform, which is designed to deliver multiple naturally occurring growth factors and proteins that may support tissue repair and reduce inflammation. KALA BIO’s lead investigational product candidate, KPI-012, is being developed for the treatment of persistent corneal epithelial defects, a condition in which the surface of the cornea does not heal properly.
Further Reading
- Five stocks we like better than KALA BIO
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
